Mustang Bio Inc diskutieren
Mustang with positive data for a lentiviral gene therapy
The FDA designates Mustang Bio's (MBIO +0.8%) CAR-T candidate MB-102 an Orphan Drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and incurable blood cancer with a median survival of less than 18 months with no effective treatment options.
Es gibt keinen Handelsplatz
Buy mit Kursziel 3,9
Buy Mustang Bio Inc
Buy Mustang Bio Inc
Sell Mustang Bio Inc
Buy Mustang Bio Inc
Sell Mustang Bio Inc
Buy Mustang Bio Inc
Sell Mustang Bio Inc
Sell Mustang Bio Inc
Buy mit Kursziel 3,0
Buy Mustang Bio Inc
Neueste Beiträge
WatchMen in Taseko Mines Ltd diskutieren